Physician profile
Daniel Charnoff
NPI 1922006832
$2,939.36
in general payments reported to CMS, 2019-2025
21 companies · $136 in 2025
The $136 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172 · 2020: $375 · 2021: $946 · 2022: $258 · 2023: $517 · 2024: $535 · 2025: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,187.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $656.15 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $645.29 | 2019-2025 | Eliquis, Camzyos |
| Mannkind Corporation | $303.80 | 2021 | |
| Lilly USA, LLC | $282.13 | 2021-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $261.63 | 2023-2024 | Shingrix, Arexvy |
| Esperion Therapeutics, INC. | $233.40 | 2020-2025 | Nexletol |
| Amgen INC. | $125.00 | 2024 | Repatha |
| Eisai INC. | $93.23 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $59.27 | 2022-2025 | Farxiga |
| Janssen Pharmaceuticals, INC | $33.86 | 2019-2020 | |
| Allergan, INC. | $33.13 | 2019-2020 | |
| Viiv Healthcare Company | $25.98 | 2022 | |
| Boston Scientific Corporation | $25.17 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $23.98 | 2022 | |
| Dexcom, INC. | $22.96 | 2024 | Dexcom G6 Transmitter |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $21.69 | 2023 | Kristalose |
| Althera Pharmaceuticals LLC | $20.41 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $20.07 | 2021 | |
| Abbvie INC. | $19.23 | 2021 | |
| Astellas Pharma US INC | $18.90 | 2019 | |
| Vistapharm, INC. | $14.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Charnoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.